Table I.
Basic characteristics of trials included in this study.
| Trial (Refs.) | Country | Site of tumor | Enrolled patients
|
Chemotherapy regimen | Dose of Ca/Mg
|
Placebo | ||
|---|---|---|---|---|---|---|---|---|
| Ca/Mg | Control | Ca | Mg | |||||
| Grothey et al 2011 (19) | USA | Colorectal | 50 | 52 | FOLFOX-4, FOLFOX-6 | 1 g | 1 g | Identical appearance |
| Dong et al 2010 (20) | China | Gastrointestinal tract | 29 | 31 | FOLFOX-4 | 1 g | 1 g | Normal saline l |
| Ishibashi et al 2010 (21) | Japan | Colorectal | 17 | 16 | mFOLFOX-6 | 0.85 g | 0.72 g | 5% glucose |
| Chay et al 2010 (22) | Singapore | Colorectal | 13 | 14 | XELOX, FOLFOX-4 | 1 g | 1 g | Normal saline |
FOLFOX-4, 2-h infusion of leucovorin (200 mg/m2/d) followed by a fluorouracil bolus (400 mg/m2/d) and 22-h infusion (600 mg/m2/d) for two consecutive days every 2 weeks, together with oxaliplatin 85 mg/m2 as a 2-h infusion on day 1; mFOLFOX-6: 2-h infusion of leucovorin (400 mg/m2) followed by a fluorouracil bolus (400 mg/m2) and 46-h infusion (2,400 mg/m2) every 2 weeks, together with oxaliplatin 85 mg/m2 as a 2-h infusion on day 1; XELOX, oral capecitabine 1000 mg/m2 twice a day for Days 1–14 and oxaliplatin 130 mg/m2 on Day 1 every 21 days; Ca/Mg, calcium gluconate and magnesium sulfate, which were used on the first day of chemotherapy.